Dry powder composition comprising long-chain RNA
The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.
1. A method for expression of a polypeptide in a subject comprising administering to the subject an effective amount of a pharmaceutical composition comprising a dry powder composition comprising a long-chain RNA molecule comprising at least 200 nucleotides, wherein the dry powder has a residual moisture content of 7% (w/w) or less, wherein the long-chain RNA molecule is in a complex with a cationic or polycationic carrier, wherein the pharmaceutical composition is formulated for mucosal, intranasal, inhalation, or pulmonary delivery, and wherein the long-chain RNA encodes the polypeptide.
2. The method of claim 1 , wherein the dry powder composition is prepared by a method comprising the following steps:
a) providing a liquid comprising the long-chain RNA molecule,
b) spray-drying the liquid of step a) with a spray-drying device having a drying gas inlet and a drying gas outlet, wherein the drying gas has a temperature at the inlet of at least 85° C., wherein the drying gas has a temperature at the outlet of at least 50° C.
3. The method according to claim 2 , wherein the liquid of step a) further comprises at least one excipient selected from a cryoprotectant, a lyoprotectant and a bulking agent.
4. The method according to claim 2 , wherein the liquid of step a) does not contain a lipid compound.
5. The method according to claim 2 , wherein the liquid of step a) comprises a spray-drying compatible solvent.
6. The method according to claim 2 , wherein the liquid of step a) is atomized and the droplets resulting from the atomization of the liquid are characterized by a mass median aerodynamic diameter of 300 nm to 200 μm.
7. The method according to claim 1 , wherein the subject has a disorder or disease selected from the group consisting of cancer or tumor diseases, infectious diseases, autoimmune diseases, allergies or allergic diseases, monogenetic diseases, cardiovascular diseases and neuronal diseases.
8. The method according to claim 1 , wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient.
9. The method according to claim 1 , wherein the pharmaceutical composition comprises a plurality of particles.
10. The method according to claim 8 , wherein the median particle size in a volume weighted distribution of the resulting dried powder is at least 1 μm.
11. The method according to claim 8 , wherein the average sphericity of the particles in the resulting dried powder is in a range from 0.7 to 1.0.
12. The method according to claim 1 , wherein the long-chain RNA molecule comprises more than 200 nucleotides.
13. The method according to claim 1 , wherein the long-chain RNA molecule comprises at least one modification.
14. The method according to claim 2 , wherein the liquid of step a) further comprises a suspending agent and/or an osmolality of about 200 mosmol/1 to about 400 mosmol/1.
15. The method according to claim 6 , wherein at least a first pressure nozzle is used as an atomizer, optionally wherein the pressure is less than about 1 bar.
16. The method of claim 1 , wherein the dry powder comprises an average particle size of 1 μm to 20 μm.
17. The method of claim 1 , wherein the pharmaceutical composition is administered by inhalation.
18. The method of claim 1 , wherein the pharmaceutical composition is administered to the lungs of the patient.
19. The method of claim 1 , wherein the pharmaceutical composition is administered as an aerosolized formulation.
20. The method of claim 1 , wherein the dry powder has a residual moisture content of 2% to 5% (w/w).
21. The method of claim 1 , wherein the wherein the cationic or polycationic carrier comprises a cationic or polycationic polypeptide.
22. The method of claim 1 , wherein the wherein the cationic or polycationic carrier comprises a cationic or polycationic lipid.
23. The method of claim 1 , wherein the wherein the cationic or polycationic carrier comprises a cationic or polycationic polymer.
24. The method of claim 1 , wherein the pharmaceutical composition is administered by mucosal, intranasal, inhalation, or pulmonary delivery.
25. A method for expression of a polypeptide in a subject comprising:
a) providing a dry powder composition comprising a long-chain RNA molecule comprising at least 200 nucleotides, wherein the dry powder has a residual moisture content of 7% (w/w) or less, wherein the long-chain RNA molecule is in a complex with a cationic or polycationic carrier and wherein the long-chain RNA encodes the polypeptide;
b) reconstituting the dry powder composition in a pharmaceutically acceptable aqueous solvent to provide a liquid pharmaceutical composition; and
c) administering an effective amount of a pharmaceutical composition to the subject.
26. The method of claim 24 , wherein the pharmaceutical composition is administered by injection.
27. The method of claim 24 , wherein the pharmaceutical composition is administered as an aerosolized formulation for mucosal, intranasal, inhalation, or pulmonary delivery.
28. The method of claim 26 , wherein the RNA encodes an antigen, said method further defined as a method for stimulating an immune response.